Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -7.34%39.86B | -9.96%28.15B | -10.96%16.75B | -16.38%56.47B | -15.38%43.02B | -12.81%31.26B | -9.45%18.81B | 24.08%67.54B | 29.14%50.84B | 29.68%35.86B |
| Operating income | -7.34%39.86B | -9.96%28.15B | -10.96%16.75B | -16.38%56.47B | -15.38%43.02B | -12.81%31.26B | -9.45%18.81B | 24.08%67.54B | 29.14%50.84B | 29.68%35.86B |
| Cost of sales | ---- | 8.85%-19.16B | ---- | 16.19%-39.13B | ---- | 16.26%-21.02B | ---- | -17.98%-46.69B | ---- | -36.19%-25.1B |
| Operating expenses | 6.54%-26.89B | 8.85%-19.16B | 10.51%-11.22B | 16.19%-39.13B | 17.08%-28.77B | 16.26%-21.02B | 14.94%-12.54B | -17.98%-46.69B | -28.15%-34.7B | -36.19%-25.1B |
| Gross profit | -8.96%12.97B | -12.23%8.99B | -11.85%5.52B | -16.81%17.35B | -11.71%14.25B | -4.76%10.24B | 4.00%6.26B | 40.33%20.85B | 31.33%16.14B | 16.67%10.75B |
| Selling expenses | 4.98%-6.46B | 8.11%-4.79B | 8.99%-2.2B | 6.39%-10.06B | 2.08%-6.8B | -3.41%-5.22B | -17.90%-2.41B | -117.13%-10.74B | -162.28%-6.94B | -105.08%-5.05B |
| Administrative expenses | 7.05%-1.32B | 7.00%-1.04B | 11.04%-423.12M | 10.04%-2.34B | 7.91%-1.42B | 7.67%-1.12B | -6.54%-475.64M | -1.10%-2.6B | -15.74%-1.54B | -13.51%-1.22B |
| Research and development expenses | -675.28%-67.69M | -4,145.81%-38.47M | -3,327.00%-12.17M | 65.98%-19.87M | 10.72%-8.73M | -9.82%-906K | 49.22%-355K | -49.69%-58.42M | ---9.78M | ---825K |
| Profit from asset sales | 222.77%47.67M | ---- | 99.02%-14.9K | ---- | 1,259.31%14.77M | ---- | -673.05%-1.52M | ---- | -53.02%1.09M | ---- |
| Impairment and provision | 1.23%-380.78M | -164.43%-1.45M | 13.69%-127.03M | 3.30%2.66M | 18.66%-385.53M | -40.27%2.25M | -5.16%-147.19M | -64.00%2.58M | -44.35%-473.95M | -50.38%3.76M |
| -Other impairment is provision | 1.23%-380.78M | -164.43%-1.45M | 13.69%-127.03M | 3.30%2.66M | 18.66%-385.53M | -40.27%2.25M | -5.16%-147.19M | -64.00%2.58M | -44.35%-473.95M | -50.38%3.76M |
| Special items of operating profit | -82.42%20.27M | -6.84%693.97M | -186.10%-19.6M | 0.27%1.5B | 68.11%115.3M | 16.97%744.89M | 29.38%22.76M | 255.24%1.49B | -72.08%68.58M | 290.58%636.84M |
| Operating profit | -19.03%3.89B | -18.15%3.8B | -16.80%2.32B | -28.12%6.43B | -19.80%4.8B | -9.43%4.65B | -2.12%2.78B | 15.75%8.95B | -17.91%5.99B | -4.24%5.13B |
| Financing cost | -9.02%595.8M | 9.92%-88.19M | 62.41%202.92M | 32.02%-202.5M | 12.56%654.91M | 39.26%-97.9M | -59.74%124.94M | -53.41%-297.89M | 193.04%581.83M | -45.13%-161.2M |
| Share of profits of associates | ---- | -150.42%-12.53M | ---- | -87.45%13.75M | ---- | 3.43%24.85M | ---- | -33.58%109.56M | ---- | -73.36%24.03M |
| Share of profit from joint venture company | ---- | -299.35%-7.97M | ---- | -63.47%-19.89M | ---- | -224.44%-2M | ---- | -396.41%-12.17M | ---- | 140.24%1.6M |
| Adjustment items of earning before tax | -511.35%-66.93M | ---- | -126.48%-314.16K | ---- | -649.94%-10.95M | ---- | -45.34%1.19M | ---- | 123.46%1.99M | ---- |
| Earning before tax | -18.89%4.42B | -19.18%3.7B | -13.44%2.52B | -28.85%6.22B | -17.13%5.45B | -8.48%4.57B | -7.81%2.91B | 13.62%8.75B | -1.34%6.57B | -6.33%5B |
| Tax | 15.99%-954.28M | 15.55%-765.45M | 2.46%-462.68M | 6.72%-1.31B | 1.18%-1.14B | -5.41%-906.37M | 31.26%-474.32M | 1.92%-1.4B | -0.77%-1.15B | -9.89%-859.9M |
| After-tax profit from continuing operations | -19.66%3.46B | -20.08%2.93B | -15.58%2.06B | -33.08%4.92B | -20.51%4.31B | -11.36%3.67B | -1.25%2.44B | 17.16%7.35B | -1.78%5.42B | -9.12%4.14B |
| Earning after tax | -19.66%3.46B | -20.08%2.93B | -15.58%2.06B | -33.08%4.92B | -20.51%4.31B | -11.36%3.67B | -1.25%2.44B | 17.16%7.35B | -1.78%5.42B | -9.12%4.14B |
| Minority profit | 5.08%411.75M | -14.55%308.48M | -8.40%117.93M | 6.45%593.91M | 80.63%391.83M | 57.55%361M | -22.06%128.75M | -51.82%557.91M | -75.71%216.93M | -60.46%229.13M |
| Profit attributable to shareholders | -22.13%3.05B | -20.68%2.62B | -15.98%1.94B | -36.32%4.32B | -24.72%3.92B | -15.40%3.31B | 0.25%2.31B | 32.77%6.79B | 12.49%5.21B | -1.63%3.91B |
| Basic earnings per share | -22.13%1.4752 | -20.68%1.2673 | -15.98%0.9367 | -36.32%2.0899 | -24.72%1.8944 | -15.40%1.5978 | -15.09%1.1148 | 27.72%3.282 | 6.79%2.5165 | -7.17%1.8887 |
| Diluted earnings per share | -22.13%1.4752 | -20.68%1.2673 | -15.98%0.9367 | -36.32%2.0899 | -24.72%1.8944 | -15.40%1.5978 | -15.09%1.1148 | 27.72%3.282 | 6.79%2.5165 | -7.17%1.8887 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | Ernst & Young Huaming (Special General Partnership), Ernst & Young | -- | -- | -- | Ernst & Young Huaming (Special General Partnership), Ernst & Young | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.